Levobunolol
- Atc Codes:S01ED03
- CAS Codes:27912-14-7#47141-42-4
- PHARMGKB ID:27912-14-7#47141-42-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Vistagan; Belgium: Betagan; Czech Republic: Vistagan; France: Betagan; Germany: Vistagan; Greece: Pentila, Vistagan; Hungary: Betagan, Huma Levobulonol, Vistagan; Ireland: Betagan; Italy: Vistagan; Luxembourg: Betagan; Netherlands: Betagan; Poland: Vistagan; Portugal: Betagan; Slovakia: Vistagan; Spain: Betagan; UK: Betagan.
North America
Canada: Betagan, Levobunolol, Probeta; USA: Akbeta, Betagan, Levobunolol.
Latin America
Argentina: Betagan, Levunolol; Brazil: Betagan, B-Tablock; Mexico: Betagan.
Asia
Japan: Levobunolol, Mirol.
Drug combinations
Chemistry
Levobunolol Hydrochloride: C~17~H~25~NO~3~ HCl. Mw: 327.85. (1) 1(2H)-Naphthalenone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, hydrochloride, (-)-(S); (2)(-)-(S)-5-[3-(tert-Butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone hydrochloride. CAS-27912-14-7; CAS-47141-42-4 (levobunolol)(1979).
Pharmacologic Category
Antiglaucoma Agents; β-Adrenergic Blocking Agents. (ATC-Code: S01ED03).
Mechanism of action
Lowers intraocular pressure by reducing aqueous humor production and possibly increases outflow of aqueous humor.
Therapeutic use
To lower intraocular pressure in chronic open-angle glaucoma or ocular hypertension.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to levobunolol or any component of the formulation. Bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second- or third-degree AV block, cardiac failure, cardiogenic shock.
Warnings and precautions
Use caution with history of severe anaphylaxis to allergens. In general, patients with bronchospastic disease should not receive β-blockers. Use with caution in diabetes mellitus (may potentiate hypoglycemia and/or mask signs and symptoms). Use with caution in heart failure. Use with caution in myasthenia gravis (may worsen disease). Use with caution in peripheral vascular disease (including Raynaud’s). Use with caution in history of psychiatric illness (may cause or exacerbate CNS depression). Some products contain benzalkonium (caution with contact lens wearers). Ophthalmic solutions contain metabisulfite. Systemic absorption and adverse effects may occur with ophthalmic use, including bradycardia and/or hypotension.